STAT Plus: Pharmalittle: Pay-to-play clinical trials draw scrutiny; Chinese drug ingredients called U.S. threat
Good morning. Elizabeth Cooney here again, subbing from Boston HQ for the vacationing Ed Silverman. Here’s what we’re watching today:
Amid rising concern, pay-to-play clinical trials are drawing scrutiny from the FDA, which has asked a committee to consider how the research community should handle clinical trials that rely on the controversial funding mechanism, STAT reports. Some clinical trials have asked participants to pay $7,000 or so to enroll. Another wanted to ask for upward of $250,000.
Continue to STAT Plus to read the full story…
